Advanstar for sale

Share this article:

Advanstar, the largest commercial medical publisher in the U.S., is up for sale.

Well, maybe.

After earlier dismissing talk of a sale as "highly speculative" "market rumors," the business publishing powerhouse today released a statement saying it is "exploring strategic alternatives, including a possible sale of the company," but cautioning that "there can be no assurance that the exploration of strategic alternatives will lead to a transaction."

The sale, first reported in Sunday's New York Post, follows that of six Advanstar divisions to Questex in April for $185 million. The firm, which now holds Life Sciences, Fashion and Powersports portfolios, divested its IT & Communications, Travel & Hospitality, Beauty, Home Entertainment, Abilities and Portfolio groups in the April sale.     

Advanstar's owner, Credit Suisse First Boston, declined comment.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Media

Programmatic buying stands to disrupt healthcare marketing

Programmatic buying stands to disrupt healthcare marketing

Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.

Five things for pharma marketers to know: Wednesday, October 22

Five things for pharma marketers to know: ...

Novo partners with YouTube star for diabetes vids; hedge fund wants Amgen to split up; J&J ramps up Ebola vaccine production.

Mucinex gets a revamp

Mucinex gets a revamp

After 10 years of "Mucinex In. Mucus Out," the congestion-relief treatment gets a new look from Reckitt Beckinser's recently appointed AOR McCann New York.